Capricor Therapeutics To Present 24-Month Results From Ongoing HOPE-2 Open Label Extension Study Of CAP-1002 In Duchenne Muscular Dystrophy
Portfolio Pulse from Benzinga Newsdesk
Capricor Therapeutics (NASDAQ:CAPR) will present 24-month safety and efficacy results from its ongoing HOPE-2 open-label extension study of CAP-1002 for Duchenne Muscular Dystrophy at the Parent Project Muscular Dystrophy Annual Conference on June 30, 2023.
June 13, 2023 | 1:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Capricor Therapeutics' presentation of 24-month results from its HOPE-2 study of CAP-1002 for Duchenne Muscular Dystrophy may impact its stock price.
The presentation of positive 24-month results from Capricor's HOPE-2 study of CAP-1002 for Duchenne Muscular Dystrophy at the PPMD Annual Conference may generate investor interest and potentially lead to an increase in the company's stock price. The conference is a significant event in the field, attended by thousands of researchers, caregivers, and patients.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100